These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 16308974)
1. [Prognostic and predictive factors in breast cancer]. Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974 [TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J; J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604 [TBL] [Abstract][Full Text] [Related]
3. [Biological features of breast cancer in patients under 35]. Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136 [TBL] [Abstract][Full Text] [Related]
4. Molecular prognostic factors for breast cancer metastasis and survival. Esteva FJ; Sahin AA; Cristofanilli M; Arun B; Hortobagyi GN Semin Radiat Oncol; 2002 Oct; 12(4):319-28. PubMed ID: 12382190 [TBL] [Abstract][Full Text] [Related]
5. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Zhou B; Yang DQ; Xie F Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105 [TBL] [Abstract][Full Text] [Related]
6. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635 [TBL] [Abstract][Full Text] [Related]
7. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)]. Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223 [TBL] [Abstract][Full Text] [Related]
8. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Dowsett M; Dunbier AK Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018 [TBL] [Abstract][Full Text] [Related]
9. [Pathologic diagnosis and histopathology record of breast cancer]. Cserni G; Francz M; Járay B; Kálmán E; Kovács I; Kulka J; Orosz Z; Udvarhelyi N; Vass L Magy Onkol; 2010 Sep; 54(3):217-26. PubMed ID: 20870599 [No Abstract] [Full Text] [Related]
10. Biological markers in breast cancer prognosis and treatment. Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH J BUON; 2010; 15(3):447-54. PubMed ID: 20941809 [TBL] [Abstract][Full Text] [Related]
11. Tumour-related factors and prognosis in breast cancer detected by screening. Olsson A; Borgquist S; Butt S; Zackrisson S; Landberg G; Manjer J Br J Surg; 2012 Jan; 99(1):78-87. PubMed ID: 22068957 [TBL] [Abstract][Full Text] [Related]
12. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board. Ellis MJ J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793 [No Abstract] [Full Text] [Related]
13. [Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast]. Nizze H; al-Thobhani AK; Terpe H Zentralbl Chir; 1998; 123 Suppl 5():14-8. PubMed ID: 10063564 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for breast cancer and their use in the clinical setting. Kapoor A; Vogel VG Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524 [TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in breast cancer patients]. Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662 [No Abstract] [Full Text] [Related]
16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550 [TBL] [Abstract][Full Text] [Related]
18. The importance of prognostic factors in premenopausal women with breast cancer. Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790 [TBL] [Abstract][Full Text] [Related]
19. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215 [TBL] [Abstract][Full Text] [Related]
20. Molecular and genetic markers in the local-regional management of breast cancer. Haffty BG Semin Radiat Oncol; 2002 Oct; 12(4):329-40. PubMed ID: 12382191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]